| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C21H27N5O2S |
| Molar mass | 413.54 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Lupitidine (INN;lupitidine hydrochloride (USAN); development codeSKF-93479) is a long-actingH2 receptor antagonist[1] developed bySmith, Kline & French and described as anantiulcerogenic that was never marketed.[2] It was shown to inhibit nocturnalgastric acid secretion[3] and, in experiments on rodents, produced diffuse neuroendocrine cell hyperplasia and an increase in multifocal glandular hyperplasia due tohypergastrinemia resulting from the pharmacological suppression of gastric acid secretion.[4]
Thisdrug article relating to thegastrointestinal system is astub. You can help Wikipedia byexpanding it. |